Could a common sleep aid ease Parkinson's symptoms?

NCT ID NCT07375693

ENROLLING_BY_INVITATION Symptom relief Sponsor: Bangladesh Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether taking 10 mg of melatonin daily for 12 weeks can reduce oxidative stress and improve symptoms in 70 people with mild-to-moderate Parkinson's disease who are already on levodopa. Participants will be randomly assigned to receive melatonin or a placebo, and researchers will measure blood markers of oxidative stress and inflammation, as well as symptom scores. The goal is to see if this widely available sleep supplement offers additional benefits beyond standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: melatonin
What this could lead to: If it works, this could point toward a simple, low-cost way to ease Parkinson's symptoms and slow disease progression by reducing oxidative stress.
What could go wrong: This is a small, early-phase trial with only 70 participants over 12 weeks. Melatonin is generally safe, but it may not provide meaningful symptom improvement or affect long-term disease course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Bangladesh medical university

Dhaka, Dhaka Division, 1212, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.